Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company that develops and markets two FDA-approved first-in-class NHE3 inhibitor drugs—IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in dialysis patients—generating over $400M in 2025 revenue and pursuing pipeline expansion in additional indications and international markets.
- Company typePublic
- Founded2009
- HeadquartersFremont, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ardelyx does
Ardelyx, Inc. (NASDAQ: ARDX) is a commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts that develops novel oral therapeutics based on its proprietary NHE3 (sodium-hydrogen exchanger 3) inhibitor platform. Founded in 2007 and led by President and CEO Mike Raab since 2009, Ardelyx has commercialized two FDA-approved first-in-class products containing the active ingredient tenapanor: IBSRELA, approved for irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH, the first and only FDA-approved phosphate absorption inhibitor for chronic kidney disease patients on dialysis with hyperphosphatemia. The company's pipeline includes RDX10531, a next-generation NHE3 inhibitor in preclinical development, plus Phase 3 trials expanding tenapanor into chronic idiopathic constipation and pediatric IBS-C populations.
The company generates revenue primarily through direct U.S. product sales of IBSRELA and XPHOZAH, supported by a specialty sales force targeting gastroenterologists, nephrologists, and primary care physicians, complemented by patient services through ArdelyxAssist. International revenue is sourced through licensing and royalty arrangements with Kyowa Kirin for Japan (where tenapanor is marketed as PHOZEVEL for hyperphosphatemia) and Shanghai Fosun Pharmaceutical for China (marketed as Wan Ti Le). Total 2025 product revenue was approximately $407 million (with IBSRELA at $274M growing 73% year-over-year and XPHOZAH at $103.6M), and Q1 2026 revenue reached $93.4 million (+38% year-over-year), with management guiding to $520–550M for full-year 2026 and targeting $1 billion in annual IBSRELA revenue by 2029. Patent protection for tenapanor formulations extends through November 2042 following a recent patent extension, and the company is publicly listed on NASDAQ with a market capitalization of approximately $1.58 billion as of April 2026.
Ardelyx firmographics
Firmographics- Name
- Ardelyx
- Legal name
- Ardelyx, Inc.
- Website
- https://ardelyx.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Ardelyx is a commercial-stage biopharmaceutical company that develops and markets two FDA-approved first-in-class NHE3 inhibitor drugs—IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in dialysis patients—generating over $400M in 2025 revenue and pursuing pipeline expansion in additional indications and international markets.
- Ownership category
- akta.pro rank
Ardelyx industry classification
Industry- Product category
- Specialty Pharmaceuticals (Gastroenterology and Nephrology)
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industry
- Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)
Keywords
Where Ardelyx is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Ardelyx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Revenue model
- Product Sales - IBSRELA: Revenue from direct product sales of IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in the United States. IBSRELA generated $274 million in 2025 revenue, up 73% year-over-year, with Q1 2026 revenue of $70.1 million up 58% YoY.
- Product Sales - XPHOZAH: Revenue from direct product sales of XPHOZAH (tenapanor) for chronic kidney disease with hyperphosphatemia in the United States. XPHOZAH generated $103.6 million in 2025 revenue, though facing headwinds from Medicare Part D reimbursement changes.
- Licensing/Royalties - Japan (Kyowa Kirin): Royalty and milestone payments from Kyowa Kirin collaboration for tenapanor in Japan, where it is marketed as PHOZEVEL. Includes upfront payments, regulatory approval milestones, sales targets, and future royalties.
- Licensing/Royalties - China (Fosun): Exclusive license agreement with Shanghai Fosun Pharmaceutical for development and commercialization of tenapanor for IBS-C and hyperphosphatemia in China, where it is marketed as Wan Ti Le.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Ardelyx product offering
Product offeringCore offering
Ardelyx is a commercial-stage biopharmaceutical company that develops and sells FDA-approved oral therapeutics based on its proprietary NHE3 inhibitor platform. Its two marketed products, IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in adults and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis, are sold directly to U.S. prescribers through its own sales force and specialty distribution, while ex-U.S. rights are licensed to Kyowa Kirin (Japan) and Shanghai Fosun Pharmaceutical (China). The company also operates ArdelyxAssist, a patient access and affordability services program supporting its products.
Product overview
Ardelyx is a commercial-stage biopharmaceutical company that has developed and commercialized two FDA-approved first-in-class medications: IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis. Both products share the same active ingredient (tenapanor) but target different indications through the same NHE3 inhibition mechanism. The company supports its products through ArdelyxAssist, a patient services program offering access and affordability support. Ardelyx's pipeline includes RDX10531 (a next-generation NHE3 inhibitor) and multiple Phase 3 clinical trials expanding tenapanor into pediatric IBS-C and chronic idiopathic constipation indications.
Differentiator
Problem solved
Functional benefit
Brands
- IBSRELA: FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, containing tenapanor as the active ingredient.
- XPHOZAH
- ArdelyxAssist
Products and services
- IBSRELA (tenapanor) FDA-approved oral medication for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. It is a first-in-class NHE3 (sodium-hydrogen exchanger 3) inhibitor that works by decreasing phosphate absorption through the gastrointestinal tract, providing rapid and sustained symptom relief.
- XPHOZAH (tenapanor) FDA-approved oral phosphate absorption inhibitor for adults with chronic kidney disease on dialysis who have inadequate response to phosphate binders, for serum phosphorus control. First and only FDA-approved therapy in its class for this indication, leveraging the same NHE3 inhibitor mechanism as IBSRELA.
- ArdelyxAssist Innovative, digital-forward, high-touch patient services program providing access and affordability support for patients prescribed Ardelyx medicines, including copay assistance for eligible commercially insured patients, free medication programs for those who qualify, and insurance support services.
- RDX10531 Next-generation NHE3 inhibitor in preclinical development with potential application across multiple therapeutic areas.
Quantifiable outcome
- 73% year-over-year revenue growth for IBSRELA in 2025
- +3 more outcomes
Companies that use Ardelyx
Customer profileSegments4 records
Ideal customer profiles3 records
Ardelyx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Ardelyx partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship, core and minor.
- Ladies Professional Golf Association (LPGA)flagshipMulti-year partnership naming Ardelyx as official corporate pharmaceutical Marketing Partner of the LPGA Tour to break stigma around digestive health issues, particularly IBS-C affecting over 90% of women. Includes digital content, player ambassadors, and custom storytelling across LPGA platforms.
- Kyowa Kirin Co. Ltd.coreStrategic collaboration for development and commercialization of tenapanor for cardiorenal diseases including hyperphosphatemia in Japan. Tenapanor is approved and marketed as PHOZEVEL for improvement of hyperphosphatemia in adult CKD patients on dialysis in Japan.
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.coreExclusive license agreement for development and commercialization of tenapanor for IBS-C and hyperphosphatemia in China. Tenapanor is approved and marketed under the Chinese trade name Wan Ti Le for patients with CKD on hemodialysis with hyperphosphatemia.
- MassBiominorMember of industry organization supporting innovation and improving patient outcomes in Massachusetts.
- California Life SciencesminorMember of California life sciences industry organization.
- Texas Healthcare and Bioscience InstituteminorMember of Texas healthcare and bioscience industry organization.
- BIO (California and Pennsylvania Affiliates)minorMember of BIO industry organization affiliates in California and Pennsylvania.
- Life Science Cares BostonminorCommunity partnership through industry-wide effort pooling resources and volunteer hours to support nonprofits in the Boston area.
- Life Science Cares Bay AreaminorCommunity partnership supporting nonprofits in the Bay Area through pooled industry resources and volunteer efforts.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Ardelyx competitors and assessment
Company assessmentBroad incumbents
- AstraZeneca: AstraZeneca markets FARXIGA (dapagliflozin), a leading CKD and cardiorenal therapy, and through its Alexion rare disease unit competes in adjacent nephrology indications; Ardelyx chairman David Mott previously led MedImmune's $15.6B sale to AstraZeneca, highlighting the strategic overlap.
- Amgen: Amgen is a major nephrology/cardiorenal player (EPOGEN, Repatha, Tezspire partnerships) with broad hospital and nephrologist relationships, and via its Horizon Therapeutics acquisition has overlapping rare disease infrastructure relevant to the XPHOZAH launch.
- AbbVie: AbbVie holds U.S. co-marketing rights to LINZESS (with Ironwood), giving it direct exposure to the IBS-C market Ardelyx targets, alongside a much broader immunology, oncology and neuroscience portfolio that dwarfs Ardelyx in scale.
- Takeda Pharmaceutical: Takeda owns AMITIZA (lubiprostone), a competing chronic constipation/IBS-C therapy, and through its broader rare disease and GI portfolio competes in adjacent specialty pharmacy channels relevant to Ardelyx.
Emerging players
- Shield Therapeutics: Shield Therapeutics markets ACCRUFeR (ferric maltol), an oral iron therapy for iron deficiency in CKD, addressing the same dialysis and CKD patient population as XPHOZAH but for a different comorbidity, making it a partial overlap.
- Cara Therapeutics: Cara Therapeutics is an emerging biopharma developing therapies for chronic kidney disease-associated pruritus (KORSUVA), sharing the dialysis patient population and nephrology channel that XPHOZAH targets, but with a different symptom focus.
Direct peers
- Travere Therapeutics: Travere is a commercial-stage biopharma focused on rare kidney diseases, with FDA-approved therapies (FILSPARI, sparsentan for IgAN) targeting the same nephrology specialist channel that Ardelyx relies on for XPHOZAH, and overlapping investor audience in renal therapeutics.
- Ironwood Pharmaceuticals: Ironwood markets LINZESS (linaclotide), the leading prescribed therapy for IBS-C and chronic idiopathic constipation in the U.S., making it the most direct head-to-head competitor to IBSRELA in the same patient population and prescriber base (gastroenterologists).
- Salix Pharmaceuticals: Salix (a Bausch Health gastroenterology-focused specialty business) markets multiple GI therapies including rifaximin and targets the same gastroenterologist prescriber base as IBSRELA, with overlapping sales infrastructure and access/reimbursement expertise.
Regional players
- Vifor Pharma: Vifor Pharma (a CSL Vifor subsidiary) is a Switzerland-based leader in iron deficiency and nephrology therapies (including intravenous iron and phosphate binders), serving as a global, non-U.S.-dominant renal therapeutics competitor relevant to Ardelyx's international tenapanor expansion.
Market position
Strengths5 records
Competitive moat4 records
Key risks3 records
Key highlights7 records
Customer concentration
Ardelyx social profiles
Digital presenceArdelyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ardelyx leadership team
Management profileNumber of profiles
Profiles16 records
Ardelyx funding detail
Funding detailFunding overview
Funding rounds11 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ardelyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ardelyx
What does Ardelyx do?
Ardelyx is a commercial-stage biopharmaceutical company that develops and sells FDA-approved oral therapeutics based on its proprietary NHE3 inhibitor platform. Its two marketed products, IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in adults and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis, are sold directly to U.S. prescribers through its own sales force and specialty distribution, while ex-U.S. rights are licensed to Kyowa Kirin (Japan) and Shanghai Fosun Pharmaceutical (China). The company also operates ArdelyxAssist, a patient access and affordability services program supporting its products.
Is Ardelyx a public or private company?
Ardelyx is a public company. It is classified as public and is currently operating.
When was Ardelyx founded?
Ardelyx was founded in 2009. It employs 251 to 500 people.
Where is Ardelyx based?
Ardelyx is headquartered in Fremont, United States, in the North America region.
How does Ardelyx make money?
Four revenue lines are on record. Product Sales - IBSRELA is the primary driver. The others are product Sales - XPHOZAH, licensing/Royalties - Japan (Kyowa Kirin) and licensing/Royalties - China (Fosun).
Who are Ardelyx's main competitors?
Broad incumbents on record are AstraZeneca, Amgen, AbbVie and Takeda Pharmaceutical. Emerging players are Shield Therapeutics and Cara Therapeutics. Direct peers are Travere Therapeutics, Ironwood Pharmaceuticals and Salix Pharmaceuticals. Vifor Pharma is listed as a regional player.
Does Ardelyx have an API?
No public API is recorded for Ardelyx.
What industry is Ardelyx in?
Ardelyx's product category is Specialty Pharmaceuticals (Gastroenterology and Nephrology). Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAIAI, Rare Renal & Nephrology Disorder Therapies. Its NAICS code is 325411 and its SIC code is 5122.